Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 7, 1998, Pages 547-552

  Van den Broek, J ^a   Mfinanga, S ^b   Moshiro, C ^c   O'Brien, R ^d   Mugomela, A ^e   Lefi, M ^f  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

^b Central Tuberculosis Reference Laboratory   (Tanzania)

^c UNIVERSITY OF DAR ES SALAAM   (Tanzania)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Bugando Medical Centre   (Tanzania)

^f National Tuberculosis and Leprosy Control Programme (NTLP)   (Tanzania)

Author keywords

HIV; Outcome of treatment; Survival; Tanzania; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TANZANIA; TUBERCULOSIS;

EID: 0031874325     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. van Cleeff M R A, Chum H J. The proportion of tuberculosis cases in Tanzania attributable to human immunodeficiency virus. Int J Epidemiol 1995; 24: 637-642.
2. Narain J P, Raviglione M C, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tubercle Lung Dis 1992; 73: 311-321.
3. Chum H J, OBrien R J, Chonde T M. et al. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS 1996; 10: 299-309.
4. van den Broek J, Borgdorff M W, Pakker N G, et al. HIV-1 infection as a risk factor for the development of tuberculosis: a case-control study in Tanzania, Int J Epidemiol 1993; 22: 1159-1165.
5. Lucas S B, De Cock K M, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308: 1531-1533.
6. Jones B E, Young S M M, Antoniskis D, et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-1297.
7. Githui W, Nunn P, Juma E, et al. Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results. Tubercle Lung Dis 1992; 73: 203-209.
8. Okwera A, Whalen C, Byekwaso F, et al. Randomized trial of thiacetazone and rifampicin-containing regimen for pulmonary tuberculosis. Lancet 1994; 344: 1323-1328.
9. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet 1993; 342: 332-337.
10. Small P M, Schecter G F, Goodman P C, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
11. Perriens J H, Colebunders R L, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative pulmonary tuberculosis treated with 'standard' chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-755.
12. Elliott A M, Halwimdi B, Hayes R J, et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two year follow-up of a cohort in Lusaka, Zambia. Trans Roy Soc Trop Med Hyg 1995; 98: 9-21.
13. Richter C, Koelemay M J W, Swai A B M, et al. Predictive markers of survival in HIV-seropositive and in HIV-seronegative Tanzanian patients with extrapulmonary tuberculosis. In: Extra-pulmonary tuberculosis and HIV infection in Tanzania. Dordrecht; ICG Printing, 1996.
14. Elliott A M, Halwimdi B, Hayes R J, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans Roy Soc Trop Med Hyg 1995; 89: 78-82.
15. World Health Organization. Treatment of tuberculosis: guidelines for National Programmes. 2nd ed. WHO/TB/97.220. Geneva; WHO 1997.
16. McLarty D. Policy implications of adult morbidity and mortality. A preliminary report. University of Dar es Salaam, Tanzania. December 1993.
17. Mighori G B, Borghesi A, Adriko C, et al. Tuberculosis and HIV infection association in a rural district of northern Uganda: epidemiological and clinical considerations. Tubercle Lung Dis 1992; 73: 285-290.
18. Morgan D, Malamba S, Okpongo M, et al. HIV disease progression and median survival in a rural Ugandan cohort. XIe International Conference on AIDS. Vancouver, July 1996. Abstract Tu.B. 310.
19. Salinari R K, Chiabrera F, Ceravolo C. Preliminary survival analysis of AIDS data from Goma, Zaire. Tropical Doctor 1990; 20: 169-170.
20. Mbaga K J, Pallangyo M, Bakari M, Aris E A. Survival time of patients with Acquired immune deficiency syndrome: experience with 274 patients in Dar es Salaam. E African Med J 1990; 67: 95-96.
21. Molina-Gamboa J D, Ponce-de-Leon S, Sifuentes-Osorino J, et al. Mycobacterial infection in Mexican AIDS patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 53-58.
22. National Tuberculosis and Leprosy Programme of Tanzania. Annual Reports 1990-1995. Dar-es Salaam, Tanzania.
23. Whalen C, Horsburgh, C R, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-135.
24. Wallis R S, Vjecha M, Amir-Tahmasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta-2-microglobulin in HIV-1 associated tuberculosis. J Infect Dis 1993; 167: 43-48.